Truly excited to announce the publication of our preclinical study!

Truly excited to announce the publication of our preclinical study, conducted in collaboration with IFF, where we evaluated the effects of Lactobacillus acidophilus NCFM and chitinglucan — both individually and combined —on intestinal pain and inflammation.
Impressively, the simultaneous oral administration of these compounds resulted in a twofold superior visceral analgesic effect compared to using each compound alone, showcasing their synergistic properties.
Beyond providing significant pain relief, this combination also exhibited strong anti-inflammatory effects, effectively reducing colonic inflammatory lesions and offering sustained relief over time. This synbiotic formulation, BK002, is currently under clinical investigation.

Read the full study, just published here.